SCHEMBL5594953

SCHEMBL5594953

O=[N+]([O-])c1ccccc1COc1ccccc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.55
HTR1A P08908 1/20 0.52
ADRA1D P25100 1/20 0.52
ADRA1A P35348 1/20 0.52
ADRA1B P35368 1/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
RECQL P46063 1/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 8/20 0.49
HTT P42858 2/20 0.49
TSHR P16473 1/20 0.49
LMNA P02545 2/20 0.48
CCR5 P51681 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
POLB P06746 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823290 0.93 MAOB (0.49) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL10789091 0.87 NPC1 (0.68) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL5860355 0.84 ALDH1A1 (0.46) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL7598113 0.81 HTR1A (0.55) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL3359449 0.81 HTR1A (0.52) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL16273706 0.80 MAOB (0.51) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL16273710 0.80 NPC1 (0.54) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL29350150 0.80 TAAR1 (0.46) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL21545836 0.80 KMT2A (0.59) MAOBHTR1AADRA1DADRA1AADRA1B
SCHEMBL9489214 0.79 MAOB (0.72) MAOBHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-59010555-A None JP disclosed
US-11753431-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2023-09-12 US disclosed
US-11753431-B2 Compounds comprising cleavable linker and uses thereof INTOCELL, INC. (KR) 2023-09-12 US disclosed
US-20210393795-A1 COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF INTOCELL, INC. (KR) 2021-12-23 US disclosed
US-20210388017-A1 COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF INTOCELL, INC. (KP) 2021-12-16 US disclosed
WO-2020141460-A2 COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF INTOCELL, INC. (KR) 2020-07-09 WO disclosed
WO-2019008441-A1 COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF INTOCELL, INC. (KR) 2019-01-10 WO disclosed
EP-0809492-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2007-01-24 EP disclosed
CN-1539816-A IL-8 receptor antagonists ʷ��˿�������ȳ�ķ���޹�˾ 2004-10-27 CN disclosed
EP-1185261-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-02-25 EP disclosed
WO-2000076495-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2000-12-21 WO disclosed
US-6005008-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-12-21 US disclosed
CN-1215990-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORP (US) 1999-05-05 CN disclosed
US-5886044-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1999-03-23 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed
JP-S5910555-A PHOTODEGRADATIVE AROMATIC ETHER COMPOUND TOSHIBA CORP 1984-01-20 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210388017-A1 COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF VIP, ANTXR2, TNFRSF9 MAOB 1931/4885HTR1A 2361/4885ADRA1D 4556/4885
US-11753431-B2 Compounds comprising cleavable linker and uses thereof VIP, ANTXR2, TNFRSF9 MAOB 1931/4885HTR1A 2361/4885ADRA1D 4556/4885
US-20210393795-A1 COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF ANTXR2, VIP, TNFRSF9 MAOB 1267/4885HTR1A 2090/4885ADRA1D 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.